SCHEMBL4350011

SCHEMBL4350011

Cc1c(Cl)cc(NS(=O)(=O)Cc2ccccc2)c(O)c1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
HPGD P15428 5/20 0.47
HSD17B10 Q99714 3/20 0.47
GAA P10253 2/20 0.47
ALOX15 P16050 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
MCL1 Q07820 1/20 0.47
PGAM1 P18669 1/20 0.46
TSHR P16473 1/20 0.46
ACLY P53396 1/20 0.45
MAPK1 P28482 1/20 0.45
PTK2B Q14289 1/20 0.45
KDM4E B2RXH2 4/20 0.45
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
MMP1 P03956 1/20 0.43
MMP2 P08253 1/20 0.43
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14563534 0.81 ALDH1A1 (0.46) ALDH1A1HPGDHSD17B10MCL1PGAM1
SCHEMBL13510428 0.81 MCL1 (0.60) ALDH1A1HPGDHSD17B10GAAALOX15
SCHEMBL4348426 0.80 ACLY (0.50) ALDH1A1HPGDHSD17B10MCL1PGAM1
SCHEMBL6806783 0.80 GAA (0.72) ALDH1A1HPGDHSD17B10GAAALOX15
SCHEMBL7589006 0.79 ALDH1A1 (0.50) ALDH1A1HPGDKMT2AACLYMAPK1
SCHEMBL4357672 0.76 GLO1 (0.51) ALDH1A1HPGDHSD17B10KMT2AMCL1
SCHEMBL4351839 0.76 HDAC8 (0.45) ALDH1A1HPGDHSD17B10GAAALOX15
SCHEMBL6807239 0.75 GAA (0.43) ALDH1A1HPGDHSD17B10GAAALOX15
SCHEMBL7596550 0.75 KMT2A (0.51) ALDH1A1HPGDHSD17B10ALOX15MEN1
SCHEMBL4345454 0.75 KMT2A (0.54) ALDH1A1HPGDHSD17B10GAAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-1402887-A1 New compounds for the inhibition of undesired cell proliferation and use thereof Jerini AG (DE) 2004-03-31 EP claimed
EP-1402888-A1 The use of substituted carbocyclic compounds as rotamases inhibitors Jerini AG (DE) 2004-03-31 EP claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 ALDH1A1 2565/4885HPGD 3561/4885HSD17B10 304/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 ALDH1A1 2767/4885HPGD 3127/4885HSD17B10 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.